Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Steinberg

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
European Urology Oncology|June 19, 2022
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer GroupWei Shen Tan, Gary Steinberg, J Alfred Witjes, et al.
The Journal of Urology|December 6, 2017
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter StudySiamak Daneshmand, Sanjay Patel, Yair Lotan, et al.
Nature Reviews. Urology|April 26, 2019
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018Yair Lotan, Trinity J Bivalacqua, Tracy Downs, et al.
BJU International|July 7, 2018
Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre studyAngela B Smith, Siamak Daneshmand, Sanjay Patel, et al.
BJU International|February 16, 2011
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinomaJamie Messer, Shahrokh F Shariat, James C Brien, et al.
European Urology|December 27, 2021
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder CancerMathieu Roumiguié, Ashish M Kamat, Trinity J Bivalacqua, et al.
Urologic Oncology|June 24, 2022
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center studyKamal S Pohar, Sanjay Patel, Yair Lotan, et al.
European Urology|March 21, 2020
Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder CancerHugh Mostafid, Marko Babjuk, Bernard Bochner, et al.
European Urology Focus|February 8, 2025
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing TherapiesDrupad Annapureddy, Jacob I Taylor, Ashish M Kamat, et al.
BJU International|August 26, 2024
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancerJacob I Taylor, Ashish M Kamat, Michael A O'Donnell, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
European Urology Oncology|June 19, 2022
Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer GroupWei Shen Tan, Gary Steinberg, J Alfred Witjes, et al.
The Journal of Urology|December 6, 2017
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter StudySiamak Daneshmand, Sanjay Patel, Yair Lotan, et al.
Nature Reviews. Urology|April 26, 2019
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018Yair Lotan, Trinity J Bivalacqua, Tracy Downs, et al.
BJU International|July 7, 2018
Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre studyAngela B Smith, Siamak Daneshmand, Sanjay Patel, et al.
BJU International|February 16, 2011
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinomaJamie Messer, Shahrokh F Shariat, James C Brien, et al.
European Urology|December 27, 2021
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder CancerMathieu Roumiguié, Ashish M Kamat, Trinity J Bivalacqua, et al.
Urologic Oncology|June 24, 2022
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center studyKamal S Pohar, Sanjay Patel, Yair Lotan, et al.
European Urology|March 21, 2020
Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder CancerHugh Mostafid, Marko Babjuk, Bernard Bochner, et al.
European Urology Focus|February 8, 2025
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing TherapiesDrupad Annapureddy, Jacob I Taylor, Ashish M Kamat, et al.
BJU International|August 26, 2024
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancerJacob I Taylor, Ashish M Kamat, Michael A O'Donnell, et al.
Pageof 6